Clicky

Transcenta Holding Limited(6628)

Description: Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials Transcenta Holding Limited has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.


Keywords: Medicine Clinical Medicine Drugs Solid Tumors Tumor Monoclonal Antibodies Osteoporosis Antibody Drug Conjugate Gastric Cancer Monoclonal Antibody Therapy Tislelizumab

Home Page: www.transcenta.com

B6-501, 218 Xinghu Street
Suzhou, 215123
China
Phone: 86 21 6237 0929


Officers

Name Title
Dr. Xueming Qian Ph.D. CEO & Exec. Director
Dr. Feng Ye Ph.D. EVP & COO
Dr. Christopher Hwang Ph.D. EVP & CTO
Dr. Yi Gu Ph.D. Sr. VP & Head of Research
Mr. Xiaolu Weng CPA Exec. VP, CFO & Exec. Director
Dr. Xichen Zhang Ph.D. Sr. VP of Manufacturing
Dr. Wen-I Chang Ph.D. Sr. VP of Oncology Franchise Strategy
Dr. Caroline Germa M.D. Exec. VP of Global Medicine Devel. & Chief Medical Officer
Ms. Kwan Wai Leung Joint Company Sec.
Ms. Wei Wang Sec.

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7656
Price-to-Sales TTM: 28.3257
IPO Date:
Fiscal Year End: December
Full Time Employees: 321
Back to stocks